Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene.
Laboratoire d'Hématologie, d'Immunologie et de Biologie des Tumeurs, CHU Paul Brousse, Villejuif, France. caroline.mayeur-rousse@pbr.aphp.fr
Caroline
C
Mayeur-Rousse
Nathalie
N
Sorel
Maud
M
Voldoire
Danielle
D
Canioni
Françoise
F
Brizard
Edouard
E
Randriamalala
Ali G
AG
Turhan
Jean-Claude
JC
Chomel
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001752:Blast Crisis / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D003561:Cytarabine / Q000008:administration & dosage; D004268:DNA-Binding Proteins / Q000235:genetics; D017809:Fatal Outcome; D015321:Gene Rearrangement; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D008297:Male; D034721:Mastocytosis, Systemic / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D009196:Myeloproliferative Disorders / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000235:genetics*; D014157:Transcription Factors / Q000235:genetics
D004268:DNA-Binding Proteins; D014157:Transcription Factors; C111777:ZMYM2 protein, human; D003561:Cytarabine; C496348:FGFR1 protein, human; D051496:Receptor, Fibroblast Growth Factor, Type 1; D015255:Idarubicin